These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 12230859

  • 1. Patent immorality?
    Bloche MG, Jungman ER.
    Am J Bioeth; 2002; 2(3):48-9. PubMed ID: 12230859
    [No Abstract] [Full Text] [Related]

  • 2. Not taking, just borrowing: government use of patented drugs.
    Ossorio PN.
    Am J Bioeth; 2002; 2(3):51-2. PubMed ID: 12230861
    [No Abstract] [Full Text] [Related]

  • 3. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
    Resnik DB, DeVille KA.
    Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852
    [No Abstract] [Full Text] [Related]

  • 4. It is not unethical, though it is often unwise, to override patents.
    Leventer H.
    Am J Bioeth; 2002; 2(3):50-1. PubMed ID: 12230860
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E.
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract] [Full Text] [Related]

  • 10. Patents: the public interest versus the private privilege.
    Parsi KP, Egan EA.
    Am J Bioeth; 2002; 2(3):45-6. PubMed ID: 12230857
    [No Abstract] [Full Text] [Related]

  • 11. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
    Schuklenk U.
    Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
    Berger JM.
    Conn J Int Law; 2002 Apr; 17(2):157-248. PubMed ID: 12688292
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
    Ghosh S.
    Fla J Int Law; 2002 Apr; 14(2):217-60. PubMed ID: 16526138
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intellectual property and pharmaceutical drugs: an ethical analysis.
    De George RT.
    Bus Ethics Q; 2005 Oct; 15(4):549-75. PubMed ID: 16358442
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.